IMJUDO
Clinical safety rating: caution
Comprehensive clinical and safety monograph for IMJUDO (IMJUDO).
Tremelimumab is a fully human IgG2 monoclonal antibody that binds to CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) expressed on activated T cells, blocking its interaction with CD80/CD86 on antigen-presenting cells, thereby enhancing T-cell activation and proliferation, including antitumor immune response.
| Metabolism | Tremelimumab is a monoclonal antibody that is eliminated via catabolism; no specific metabolic pathways or enzymes involved. |
| Excretion | Primarily cleared from plasma via target-mediated disposition; minimal renal or fecal elimination of intact drug. Based on population PK analysis, renal excretion accounts for <1% of the total clearance. |
| Half-life | Terminal half-life approximately 20.8-26.7 days (population PK estimate). The long half-life supports a 6-week dosing interval for maintenance therapy. |
| Protein binding | Approximately 81% bound to human plasma proteins. |
| Volume of Distribution | Vdss ~6.4 L (inter-individual variability 25-60% CV), indicating limited extravascular distribution. |
| Bioavailability | Not applicable; IMJUDO is administered intravenously with 100% bioavailability. |
| Onset of Action | Intravenous administration: Tumor responses often observed within 6-14 weeks after treatment initiation. |
| Duration of Action | Prolonged receptor occupancy on CD8+ T cells; clinical effect duration depends on continued dosing every 3-6 weeks. PD-L1 blockade persists throughout the dosing interval. |
400 mg intravenously over 30 minutes every 6 weeks for a maximum of 8 cycles or until disease progression or unacceptable toxicity.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment (CrCl ≥30 mL/min). Not recommended in severe renal impairment (CrCl <30 mL/min) due to lack of data. |
| Liver impairment | Mild hepatic impairment (Child-Pugh A): no adjustment. Moderate to severe (Child-Pugh B or C): not recommended due to lack of data. |
| Pediatric use | Safety and efficacy not established in pediatric patients. |
| Geriatric use | No specific dose adjustment recommended. Age-related renal function should be monitored, and patients >65 years showed similar safety and efficacy in clinical trials. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for IMJUDO (IMJUDO).
| Breastfeeding | No data are available on the presence of tremelimumab in human milk, effects on the breastfed infant, or effects on milk production. Human IgG is excreted in breast milk, and tremelimumab may be present. Because of the potential for serious adverse reactions in a breastfed infant, advise women not to breastfeed during treatment and for at least 3 months after the last dose. M/P ratio is unknown. |
| Teratogenic Risk | IMJUDO (tremelimumab) is an IgG2 monoclonal antibody. IgG crosses the placenta in increasing amounts as pregnancy progresses, with the largest transfer occurring in the third trimester. Based on its mechanism of action (CTLA-4 blockade), there is potential for fetal harm, including increased risk of immune-mediated disorders and altered fetal immune development. Human data are insufficient; animal studies are not available. Use is not recommended during pregnancy unless the maternal benefit outweighs the fetal risk, and effective contraception should be used during treatment and for at least 3 months after the last dose. |
■ FDA Black Box Warning
Immune-mediated adverse reactions, including pneumonitis, hepatitis, colitis, endocrinopathies, nephritis, and dermatitis, can be severe or fatal.
| Serious Effects |
None
| Precautions | ["Immune-mediated adverse reactions (pneumonitis, hepatitis, colitis, endocrinopathies, nephritis, dermatitis, and others)","Infusion-related reactions","Embryo-fetal toxicity"] |
Loading safety data…
| Fetal Monitoring | Monitor for immune-mediated adverse reactions (e.g., colitis, hepatitis, pneumonitis, endocrinopathies) in the mother. Fetal monitoring includes assessment for growth restriction and potential immune-mediated effects, though specific fetal monitoring guidelines are not established. Thyroid function tests, liver function tests, and assessment for signs of fetal immune dysregulation should be considered. |
| Fertility Effects | No formal fertility studies have been conducted with tremelimumab. Based on its mechanism of CTLA-4 inhibition, which may affect immune-mediated reproductive processes, there is potential for impairment of fertility in both males and females. The duration of effect is unknown; consider fertility preservation options prior to treatment. |